As temperatures drop around Germany, many newcomers will be reminded of just how long and bitingly cold the winter can be ...

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a ...

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...

Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...

Vor Biopharma's estimated fair value is US$15.10 based on 2 Stage Free Cash Flow to Equity Vor Biopharma is estimated to be 49% undervalued based on current share price of US$7.68 Our fair value ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

So I am steadily plodding towards my instrument rating IFR training. I am also trying to figure out which airplane I want to use for my IFR training. This video show the Piper Archer I want to use for ...

When you're flying on a commercial jet and going through a cloud, it's easy to wonder how pilots know where they're going, but through an assortment of tools and instruments -- like a VHF ...

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after RemeGen revealed the success of a China phase 3 trial ...

Vor Bio’s big bet on RemeGen’s autoimmune asset telitacicept appears well placed after the drug—already approved across three conditions overseas—delivered a late-stage win in a Sjögren's syndrome ...